Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of betrixaban versus warfarin in non-valvular atrial fibrillation
2008-005977-37Phase 2Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of betrixaban in Atrial fibrillation (AFib) (4 arms), sponsored by Portola Pharmaceuticals. Primary endpoint: Time to occurrence of major or clinically relevant non-major bleeding. Started Dec 2008; status: completed.
02
Drugs
betrixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2008-005977-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005977-37.